Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT... Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions. 詳細を表示
Full year revenue of ~$84.6 million represents a 15% year-over-year increase Cash balance of ~$185.0 million expected to provide runway to cash flow break-even Personalis, Inc. (Nasdaq: PSNL), a...
Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy. The company has...
Expanded collaboration to yield greater biopharma access to Personalis’ MRD solution Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.73 | -11.5506329114 | 6.32 | 6.98 | 5.22 | 1062747 | 6.05198419 | CS |
4 | 2.12 | 61.0951008646 | 3.47 | 7.19 | 3.36 | 1636101 | 5.54066369 | CS |
12 | 0.9 | 19.1897654584 | 4.69 | 7.19 | 3.28 | 997302 | 4.96729006 | CS |
26 | 4.05 | 262.987012987 | 1.54 | 7.2 | 1.49 | 1216800 | 4.65473736 | CS |
52 | 3.47 | 163.679245283 | 2.12 | 7.2 | 1.12 | 777499 | 3.99166559 | CS |
156 | -7.15 | -56.1224489796 | 12.74 | 13.44 | 0.8906 | 555352 | 3.89608841 | CS |
260 | -5.34 | -48.8563586459 | 10.93 | 53.46 | 0.8906 | 565729 | 12.19912928 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約